Scarica l'app Stockscreener
5.33
0.95%
0.05
Dopo l'orario di chiusura:
5.36
0.03
+0.56%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.28
Aprire:
$5.31
Volume 24 ore:
694.70K
Relative Volume:
0.46
Capitalizzazione di mercato:
$237.22M
Reddito:
$3.64M
Utile/perdita netta:
$-87.37M
Rapporto P/E:
-1.2968
EPS:
-4.11
Flusso di cassa netto:
$-86.46M
1 W Prestazione:
-6.98%
1M Prestazione:
+15.87%
6M Prestazione:
+55.85%
1 anno Prestazione:
-52.03%
Intervallo 1D:
$5.12
$5.42
Intervallo di 1 settimana:
$5.01
$6.02
Portata 52W:
$2.10
$14.22
Verastem Inc Stock (VSTM) Company Profile
Nome
Verastem Inc
Settore
Industria
Telefono
(781) 292-4200
Indirizzo
117 KENDRICK STREET, NEEDHAM, MA
Confronta VSTM con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.33 | 237.22M | 3.64M | -87.37M | -86.46M | -4.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-31 | Reiterato | BTIG Research | Buy |
| 2024-09-30 | Iniziato | Guggenheim | Buy |
| 2023-11-21 | Ripresa | BTIG Research | Buy |
| 2023-09-27 | Iniziato | B. Riley Securities | Buy |
| 2023-06-15 | Aggiornamento | Mizuho | Neutral → Buy |
| 2022-09-07 | Ripresa | Alliance Global Partners | Buy |
| 2022-04-29 | Ripresa | Cantor Fitzgerald | Overweight |
| 2022-04-14 | Iniziato | RBC Capital Mkts | Outperform |
| 2022-03-09 | Iniziato | Truist | Buy |
| 2021-07-01 | Iniziato | Alliance Global Partners | Buy |
| 2021-05-24 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2019-06-20 | Downgrade | BTIG Research | Buy → Neutral |
| 2019-05-10 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | Iniziato | BTIG Research | Buy |
| 2018-05-02 | Iniziato | Seaport Global Securities | Buy |
| 2018-03-08 | Iniziato | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | Reiterato | H.C. Wainwright | Buy |
| 2017-04-13 | Iniziato | Oppenheimer | Outperform |
| 2017-03-24 | Reiterato | H.C. Wainwright | Buy |
| 2015-09-29 | Downgrade | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | Downgrade | Jefferies | Buy → Hold |
| 2015-09-29 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | Downgrade | Mizuho | Buy → Neutral |
| 2015-09-28 | Downgrade | ROTH Capital | Buy → Neutral |
| 2015-09-09 | Iniziato | Raymond James | Strong Buy |
| 2015-05-12 | Reiterato | UBS | Buy |
| 2015-04-08 | Iniziato | H.C. Wainwright | Buy |
| 2015-01-23 | Reiterato | ROTH Capital | Buy |
| 2014-07-08 | Ripresa | Oppenheimer | Perform |
| 2014-02-11 | Iniziato | Mizuho | Buy |
Mostra tutto
Verastem Inc Borsa (VSTM) Ultime notizie
Verastem Stock Soars 46% After FDA Grants Priority Review for Cancer Treatment – Market - HPBL
Verastem stock retains Buy rating as KRASG12D program and LGSOC launch gain traction - Investing.com Canada
Verastem, Inc. (NASDAQ:VSTM) Shares Sold by Jane Street Group LLC - Defense World
Verastem Oncology Names Matthew E. Ros as Chief Operating Officer - BioSpace
Verastem Oncology Names Pharma Veteran Matthew Ros as COO Ahead of Key Cancer Drug Launch - StockTitan
Verastem Oncology Appoints Matthew E. Ros as Chief Operating Officer - Marketscreener.com
Dan Paterson Sells 8,568 Shares of Verastem, Inc. (NASDAQ:VSTM) Stock - MarketBeat
Verastem CEO sells shares worth $44,896 By Investing.com - Investing.com Australia
Verastem CEO sells shares worth $44,896 - Investing.com India
Verastem licenses GenFleet's KRAS inhibitor - The Pharma Letter
Verastem Licenses Investigational Cancer Drug VS-7375 from GenFleet, Shares Rise 4.1% – Market - HPBL
Verastem Oncology: $150 Million Credit Facility Deal Signed - Pulse 2.0
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China - Business Wire
Verastem Oncology announces debt refinancing with Oberland Capital - MSN
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025 - BioSpace
Verastem Oncology Secures $150M Credit Facility, IQVIA Partnership for Cancer Drug Launch - StockTitan
Royal Bank of Canada Forecasts Strong Price Appreciation for Verastem (NASDAQ:VSTM) Stock - Defense World
FDA reviewing oral combination treatment for ovarian cancer - Myeloma Research News
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
Follicular Lymphoma Market Expected to rise, 2034 | - openPR
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Verastem's SWOT analysis: biotech firm's stock rides on avutometinib approval - Investing.com India
Barclays PLC Has $167,000 Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Geode Capital Management LLC Raises Stock Position in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem Oncology Grants Stock Options to New Employee at $6.49 Exercise Price - StockTitan
Chugai Pharmaceutical Co., Ltd.Verastem Oncology's Announcement Regarding Avutometinib - Marketscreener.com
Royal Bank of Canada Issues Positive Forecast for Verastem (NASDAQ:VSTM) Stock Price - MarketBeat
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review Tag - MSN
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of “Buy” from Analysts - Defense World
Verastem, Inc. (NASDAQ:VSTM) Receives Consensus Rating of "Buy" from Analysts - MarketBeat
Verastem: Planning The PDUFA Run-Up (NASDAQ:VSTM) - Seeking Alpha
State Street Corp Grows Holdings in Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem: BLA Acceptance Puts Key Goals In Sight (NASDAQ:VSTM) - Seeking Alpha
Verastem soars on FDA priority review for avutometinib - The Pharma Letter
Verastem stock climbs on raised price target and FDA milestone for KRASm treatment - Investing.com Nigeria
Verastem stock remains volatile but promising data reinforces Buy rating by B.Riley - Investing.com Canada
BTIG Research Issues Positive Forecast for Verastem (NASDAQ:VSTM) Stock Price - Defense World
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Thera - GuruFocus.com
Verastem Shares Soar on FDA Priority Review of Cancer Treatment - Marketscreener.com
FDA sets priority review date for Verastem’s new ovarian cancer drug - The Business Journals
Regulatory Milestone Sends Verastem (VSTM) Shares Soaring - Stocks Telegraph
Stifel Financial Corp Buys 11,642 Shares of Verastem, Inc. (NASDAQ:VSTM) - Defense World
Verastem Shares Surge Over 24% on FDA Acceptance of Cancer Therapy Application - Yahoo Finance
Verastem (NASDAQ:VSTM) Price Target Raised to $20.00 at BTIG Research - MarketBeat
Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer - BioSpace
Verastem Oncology's New Cancer Treatment Gets FDA Priority Review - Marketscreener.com
FDA accepts Verastem NDA for priority review, stock jumps 20% (update) - Seeking Alpha
Verastem Inc Azioni (VSTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.65%
4.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):